Sjef van der Linden
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sjef van der Linden has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Astrid van Tubergen
Department of Rheumatology, Maastricht University Medical Centre+, Maastricht, the Netherlands; Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, the Netherlands
2 shared publications A Hidding
1 shared publication- Arie C Nieuwenhuijzen Kruseman
Department of Internal Medicine, Division of Endocrinology, University Hospital Maastricht, The Netherlands
1 shared publication - Bianca Dumitrescu
Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania
1 shared publication - Caroline E. Wyers
Department of Internal Medicine, VieCuri Medical Center , 5912 BL Venlo
1 shared publication D van der Heijde
Department of Internal Medicine, Division of Rheumatology, University Hospital Maastricht, Maastricht, The Netherlands
1 shared publication
Latest Publications
- Open Access
- 5 August 2008
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 9 (1) , 109
Evaluation of patients with a recent clinical fracture and osteoporosis, a multidisciplinary approach
The aetiology of osteoporotic fractures is multifactorial, but little is known about the way to evaluate patients with a recent clinical fracture for the presence of secondary osteoporosis. The purpose of this study was to determine the prevalence of contributors to secondary osteoporosis in patients presenting with a clinical vertebral or non-vertebral fracture. Identifying and correcting these contributors will enhance treatment effect aimed at reducing the risk of subsequent fractures. In a multidisciplinary approach, including evaluation of bone and fall-related risk factors, 100 consecutive women (n = 73) and men (n = 27) older than 50 years presenting with a clinical vertebral or non-vertebral fracture and having osteoporosis (T-score ≤-2.5) were further evaluated clinically and by laboratory testing for the presence of contributors to secondary osteoporosis. In 27 patients, 34 contributors were previously known, in 50 patients 52 new contributors were diagnosed (mainly vitamin D deficiency in 42) and 14 needed further exploration because of laboratory abnormalities (mainly abnormal thyroid stimulating hormone in 9). The 57 patients with contributors were older (71 vs. 64 yrs, p < 0.01), had more vertebral deformities (67% vs. 44%, p < 0.05) and a higher calculated absolute 10-year risk for major (16.5 vs. 9.9%, p < 0.01) and for hip fracture (6.9 vs. 2.4%, p < 0.01) than patients without contributors. The presence of contributors was similar between women and men and between patients with fractures associated with a low or high-energy trauma. We conclude that more than one in two patients presenting with a clinical vertebral or non-vertebral fracture and BMD-osteoporosis have secondary contributors to osteoporosis, most of which were correctable. Identifying and correcting these associated disorders will enhance treatment effect aimed at reducing the risk of subsequent fractures in patients older than 50 years.
- 5 August 2008
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 9 (1) , 109
Open AccessEvaluation of patients with a recent clinical fracture and osteoporosis, a multidisciplinary approach
The aetiology of osteoporotic fractures is multifactorial, but little is known about the way to evaluate patients with a recent clinical fracture for the presence of secondary osteoporosis. The purpose of this study was to determine the prevalence of contributors to secondary osteoporosis in patients presenting with a clinical vertebral or non-vertebral fracture. Identifying and correcting these contributors will enhance treatment effect aimed at reducing the risk of subsequent fractures. In a multidisciplinary approach, including evaluation of bone and fall-related risk factors, 100 consecutive women (n = 73) and men (n = 27) older than 50 years presenting with a clinical vertebral or non-vertebral fracture and having osteoporosis (T-score ≤-2.5) were further evaluated clinically and by laboratory testing for the presence of contributors to secondary osteoporosis. In 27 patients, 34 contributors were previously known, in 50 patients 52 new contributors were diagnosed (mainly vitamin D deficiency in 42) and 14 needed further exploration because of laboratory abnormalities (mainly abnormal thyroid stimulating hormone in 9). The 57 patients with contributors were older (71 vs. 64 yrs, p < 0.01), had more vertebral deformities (67% vs. 44%, p < 0.05) and a higher calculated absolute 10-year risk for major (16.5 vs. 9.9%, p < 0.01) and for hip fracture (6.9 vs. 2.4%, p < 0.01) than patients without contributors. The presence of contributors was similar between women and men and between patients with fractures associated with a low or high-energy trauma. We conclude that more than one in two patients presenting with a clinical vertebral or non-vertebral fracture and BMD-osteoporosis have secondary contributors to osteoporosis, most of which were correctable. Identifying and correcting these associated disorders will enhance treatment effect aimed at reducing the risk of subsequent fractures in patients older than 50 years.
- 1 May 2008
- Published by Springer Nature in Wiener Medizinische Wochenschrift
- Vol. 158 (7-8) , 195-199
Issues in the Treatment of Ankylosing Spondylitis with Non-Steroidal Anti-Inflammatory Drugs
The primary aim of the management of ankylosing spondylitis (AS) is symptomatic relief and prevention of structural changes and functional decline by both pharmaceutical and non-pharmaceutical interventions. NSAIDs are frequently used, but often have adverse effects or may not be effective enough to alleviate complaints. NSAIDs and Coxibs provide comparable symptomatic relief. It has now become clear, however, that these drugs are also associated with increased cardiovascular risk, probably due to imbalance between Cox-1- and Cox-2-inhibition. Limited evidence suggests that continuous use of NSAIDs may retard progression of axial structural changes as compared to 'on-demand' usage of these drugs. A critical appraisal of a recent paper on this topic indicates that more evidence is needed before continuous use of NSAIDs or Coxibs can be recommended taking also into consideration the increase cardiovascular risks of these drugs.
- 1 May 2008
- Published by Springer Nature in Wiener Medizinische Wochenschrift
- Vol. 158 (7-8) , 195-199
Issues in the Treatment of Ankylosing Spondylitis with Non-Steroidal Anti-Inflammatory Drugs
The primary aim of the management of ankylosing spondylitis (AS) is symptomatic relief and prevention of structural changes and functional decline by both pharmaceutical and non-pharmaceutical interventions. NSAIDs are frequently used, but often have adverse effects or may not be effective enough to alleviate complaints. NSAIDs and Coxibs provide comparable symptomatic relief. It has now become clear, however, that these drugs are also associated with increased cardiovascular risk, probably due to imbalance between Cox-1- and Cox-2-inhibition. Limited evidence suggests that continuous use of NSAIDs may retard progression of axial structural changes as compared to 'on-demand' usage of these drugs. A critical appraisal of a recent paper on this topic indicates that more evidence is needed before continuous use of NSAIDs or Coxibs can be recommended taking also into consideration the increase cardiovascular risks of these drugs.
- 1 November 2006
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 65 (11) , 1518-1520
Definition of disease duration in ankylosing spondylitis: reassessing the concept
The concept and definition of disease duration in patients with ankylosing spondylitis is ambiguous, and often many years pass between the onset of symptoms and diagnosis. Members of the Assessment in Ankylosing Spondylitis (ASAS) International Working Group by consensus recently recommended identifying specific components of the medical history to better define and document the concept of disease duration. These include (1) the time of onset of the first symptoms of axial manifestations (including inflammatory back pain); (2) the time of onset of the first symptoms of each individual manifestation, which may be an extra-axial sign or symptom of ankylosing spondylitis, such as peripheral arthritis and enthesitis; (3) the time of onset of associated diseases belonging to the spondyloarthritides, in particular acute anterior uveitis, inflammatory bowel disease and psoriasis; and (4) the time since actual diagnosis by a healthcare provider. Such uniformity in data collection will ensure comparability across studies and facilitate future research.
- 1 November 2006
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 65 (11) , 1518-1520
Definition of disease duration in ankylosing spondylitis: reassessing the concept
The concept and definition of disease duration in patients with ankylosing spondylitis is ambiguous, and often many years pass between the onset of symptoms and diagnosis. Members of the Assessment in Ankylosing Spondylitis (ASAS) International Working Group by consensus recently recommended identifying specific components of the medical history to better define and document the concept of disease duration. These include (1) the time of onset of the first symptoms of axial manifestations (including inflammatory back pain); (2) the time of onset of the first symptoms of each individual manifestation, which may be an extra-axial sign or symptom of ankylosing spondylitis, such as peripheral arthritis and enthesitis; (3) the time of onset of associated diseases belonging to the spondyloarthritides, in particular acute anterior uveitis, inflammatory bowel disease and psoriasis; and (4) the time since actual diagnosis by a healthcare provider. Such uniformity in data collection will ensure comparability across studies and facilitate future research.
- Open Access
- 1 February 2005
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 8 (1) , R11
Magnetic resonance imaging changes of sacroiliac joints in patients with recent-onset inflammatory back pain: inter-reader reliability and prevalence of abnormalities
To study the inter-reader reliability of detecting abnormalities of sacroiliac (SI) joints in patients with recent-onset inflammatory back pain by magnetic resonance imaging (MRI), and to study the prevalence of inflammation and structural changes at various sites of the SI joints.Sixty-eight patients with inflammatory back pain (at least four of the five following criteria: symptom onset before age 40, insidious onset, morning stiffness, duration >3 months, improvement with exercise — or three out of five of these plus night pain) were included (38% male; mean age, 34.9 years [standard deviation 10.3]; 46% HLA-B27-positive; mean symptom duration, 18 months), with symptom duration <2 years. A MRI scan of the SI joints was made in the coronal plane with the following sequences: T1-weighted spin echo, short-tau inversion recovery, T2-weighted fast-spin echo with fat saturation, and T1-spin echo with fat saturation after the administration of gadolinium. Both SI joints were scored for inflammation (separately for subchondral bone and bone marrow, joint space, joint capsule, ligaments) as well as for structural changes (erosions, sclerosis, ankylosis), by two observers independently. Agreement between the two readers was analysed by concordance and discordance rates and by kappa statistics.Inflammation was present in 32 SI joints of 22 patients, most frequently located in bone marrow and/or subchondral bone (29 joints in 21 patients). Readers agreed on the presence of inflammation in 85% of the cases in the right SI joint and in 78% of the cases in the left SI joint. Structural changes on MRI were present in 11 patients. Ten of these 11 patients also showed signs of inflammation.Agreement on the presence or absence of inflammation and structural changes of SI joints by MRI was acceptable, and was sufficiently high to be useful in ascertaining inflammatory and structural changes due to sacroiliitis. About one-third of patients with recent-onset inflammatory back pain show inflammation, and about one-sixth show structural changes in at least one SI joint.
- 1 February 2005
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 8 (1) , R11
Open AccessMagnetic resonance imaging changes of sacroiliac joints in patients with recent-onset inflammatory back pain: inter-reader reliability and prevalence of abnormalities
To study the inter-reader reliability of detecting abnormalities of sacroiliac (SI) joints in patients with recent-onset inflammatory back pain by magnetic resonance imaging (MRI), and to study the prevalence of inflammation and structural changes at various sites of the SI joints.Sixty-eight patients with inflammatory back pain (at least four of the five following criteria: symptom onset before age 40, insidious onset, morning stiffness, duration >3 months, improvement with exercise — or three out of five of these plus night pain) were included (38% male; mean age, 34.9 years [standard deviation 10.3]; 46% HLA-B27-positive; mean symptom duration, 18 months), with symptom duration <2 years. A MRI scan of the SI joints was made in the coronal plane with the following sequences: T1-weighted spin echo, short-tau inversion recovery, T2-weighted fast-spin echo with fat saturation, and T1-spin echo with fat saturation after the administration of gadolinium. Both SI joints were scored for inflammation (separately for subchondral bone and bone marrow, joint space, joint capsule, ligaments) as well as for structural changes (erosions, sclerosis, ankylosis), by two observers independently. Agreement between the two readers was analysed by concordance and discordance rates and by kappa statistics.Inflammation was present in 32 SI joints of 22 patients, most frequently located in bone marrow and/or subchondral bone (29 joints in 21 patients). Readers agreed on the presence of inflammation in 85% of the cases in the right SI joint and in 78% of the cases in the left SI joint. Structural changes on MRI were present in 11 patients. Ten of these 11 patients also showed signs of inflammation.Agreement on the presence or absence of inflammation and structural changes of SI joints by MRI was acceptable, and was sufficiently high to be useful in ascertaining inflammatory and structural changes due to sacroiliitis. About one-third of patients with recent-onset inflammatory back pain show inflammation, and about one-sixth show structural changes in at least one SI joint.
- 5 December 2002
- Vol. 20, S60-4
Physiotherapy in ankylosing spondylitis: what is the evidence?
Evidence on the value of some current physiotherapeutic practices and the ineffectiveness of others is accumulating. This paper addresses the best evidence available on the efficacy and effectiveness of physiotherapeutic modalities in ankylosing spondylitis. General issues in the assessment of physiotherapy in this disease are briefly discussed. Core sets for assessments are nowadays available. A recent Cochrane review on this topic supports the (at least short-term) positive effects of physiotherapy in particular exercise, in the management of ankylosing spondylitis. Some details of the included studies are provided.
- 5 December 2002
- Vol. 20, S60-4
Physiotherapy in ankylosing spondylitis: what is the evidence?
Evidence on the value of some current physiotherapeutic practices and the ineffectiveness of others is accumulating. This paper addresses the best evidence available on the efficacy and effectiveness of physiotherapeutic modalities in ankylosing spondylitis. General issues in the assessment of physiotherapy in this disease are briefly discussed. Core sets for assessments are nowadays available. A recent Cochrane review on this topic supports the (at least short-term) positive effects of physiotherapy in particular exercise, in the management of ankylosing spondylitis. Some details of the included studies are provided.
- Open Access
- 1 October 2002
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 61 (10) , 948-949
Sjögren's syndrome criteria
- 1 October 2002
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 61 (10) , 948-949
Open AccessSjögren's syndrome criteria
- Open Access
- 1 October 2002
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 61 (10) , 949-950
A brief history of spa therapy
- 1 October 2002
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 61 (10) , 949-950
Open AccessA brief history of spa therapy
- 1 July 2000
- Published by Wolters Kluwer Health in Current Opinion in Rheumatology
- Vol. 12 (4) , 263-268
Clinical aspects, outcome assessment, and management of ankylosing spondylitis and postenteric reactive arthritis
The cause of ankylosing spondylitis remains unclear. Proof that this disorder is an autoimmune disease attributable to cross-reactivity between bacteria and HLA-B27 is still lacking. Differences in endogenous peptide presentation by HLA-B27 subtypes might be relevant in the etiopathogenesis. Fractures of the osteoporotic spine contribute to morbidity. Spinal cord injury may occur. MR imaging enables identifying sacroiliitis earlier than plain radiography. Sweet syndrome has now been described in patients with ankylosing spondylitis and Crohn disease. Progress has been made in the assessment of ankylosing spondylitis. There are now core sets for different settings and validated instruments for functioning and disease activity that will enable demonstrating efficacy of new therapeutic interventions.The debate continues on classification of postinfectious and reactive arthritis. Bacterial antigens may be found in the inflamed joints; occasionally 16S ribosomal RNA is also demonstrated. Antibiotics seem not to be effective in postenteric reactive arthritis.More than 25 years have now elapsed since the association between ankylosing spondylitis and HLA-B27 was first described in 1973. The cause of this disease is still unknown, but a lot of progress has been made regarding the molecular structure of HLA-B27, the spectrum of disease, the clinical and radiographic assessment of ankylosing spondylitis, and its treatment. Recent advances in research on ankylosing spondylitis are reviewed here.
- 1 July 2000
- Published by Wolters Kluwer Health in Current Opinion in Rheumatology
- Vol. 12 (4) , 263-268
Clinical aspects, outcome assessment, and management of ankylosing spondylitis and postenteric reactive arthritis
The cause of ankylosing spondylitis remains unclear. Proof that this disorder is an autoimmune disease attributable to cross-reactivity between bacteria and HLA-B27 is still lacking. Differences in endogenous peptide presentation by HLA-B27 subtypes might be relevant in the etiopathogenesis. Fractures of the osteoporotic spine contribute to morbidity. Spinal cord injury may occur. MR imaging enables identifying sacroiliitis earlier than plain radiography. Sweet syndrome has now been described in patients with ankylosing spondylitis and Crohn disease. Progress has been made in the assessment of ankylosing spondylitis. There are now core sets for different settings and validated instruments for functioning and disease activity that will enable demonstrating efficacy of new therapeutic interventions.The debate continues on classification of postinfectious and reactive arthritis. Bacterial antigens may be found in the inflamed joints; occasionally 16S ribosomal RNA is also demonstrated. Antibiotics seem not to be effective in postenteric reactive arthritis.More than 25 years have now elapsed since the association between ankylosing spondylitis and HLA-B27 was first described in 1973. The cause of this disease is still unknown, but a lot of progress has been made regarding the molecular structure of HLA-B27, the spectrum of disease, the clinical and radiographic assessment of ankylosing spondylitis, and its treatment. Recent advances in research on ankylosing spondylitis are reviewed here.